Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms
Sign Up to like & getrecommendations! Published in 2019 at "Haematologica"
DOI: 10.3324/haematol.2018.203729
Abstract: The identification of JAK-STAT pathway mutations in the majority of patients with myeloproliferative neoplasms (MPN) led to the clinical development of JAK inhibitors and resulted in the approval of ruxolitinib for MPN therapy. Despite this… read more here.
Keywords: jak inhibitor; mathematical modeling; alternative jak; modeling reveals ... See more keywords